Original Article

Immunocytochemical Detection of BCL-2 Protein in Chronic B-Cell Lymphoproliferative Disorders

Abstract

Background: The expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in B-cell chronic lymphoproliferative disorders (B-CLPDs) can provide valuable prognostic information and assist in assessing minimal bone marrow (BM) infiltration. This study aimed to detect BCL-2 expression in B-CLPDs and correlate the findings with various clinicobiologic factors.

Materials and Methods: Immunocytochemical staining was performed on mononuclear cell smears from 46 Sudanese patients, including 25 with B-cell chronic lymphocytic leukaemia (B-CLL) and 21 with B-cell non-Hodgkin’s lymphomas (B-NHL), who were enrolled during their visit to the Radiation and Isotope Centre and Fedail Hospital, Khartoum. Diagnosis was based on clinical examination, morphology, and immunophenotyping.

Results: Among the 46 B-CLPD cases, BCL-2 expression was identified in 13 (28.2%), including 8/25 (32%) cases with B-CLL and 5/21 (23.8%) with B-NHL. No statistically significant associations were found between BCL-2 expression and age, sex, total white blood cell count, disease stage, and serum lactate dehydrogenase levels (all P>0.05). However, BM involvement was significantly associated with BCL-2 expression (P=0.02).

Conclusion: The immunocytochemical staining method effectively detects BCL-2 protein in B-CLPDs, even in cases with minimal BM infiltration, thereby facilitating the correlation of this protein’s expression with morphological and other clinicobiologic features. By combining cytologic morphology with immunocytochemistry, this technique enables earlier and more accessible evaluation of BM involvement.

1. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17(7):395–417.
2. Luna-Vargas MPA, Chipuk JE. The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J. 2016; 283(14): 2676–89.
3. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3460–67.
4. Xuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017; 30(2): 194-203.
5. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012; 120(19): 3986–96.
6. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborativestudy. Blood. 2008; 112(8):3088–3098.
7. Young KH, Weisenburger DD, Dave BJ, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAIL receptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood. 2007; 110(13): 4396–405.
8. Zainuddin N, Berglund M, Wanders A, et al. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res. 2009; 33(1):60–6.
9. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood. 2012; 119(20): 4619-24.
10. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009; 114(11): 2273–9.
11. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114(17): 3533–7.
12. Snuderl M, Kolman OK, Chen YB, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010; 34(3):327–340.
13. Winter SS. Lymphoproliferative disorders. Emedicine. December 20, 2006. http://www.emedicine.com/ped/topic1345.htm. Accessed March 2007
14. Rao VK, Straus SE. Causes and consequences of the autoimmune lymph proliferative syndrome. Hematology. 2006; 11(1): 15–23.
15. Puzzo D, Loreto C, Giunta S, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging. 2014; 35(3):520-31.
16. Feidantsis K, Anestis A, Michaelidis B. Seasonal variations of anti-/apoptotic and antioxidant proteins in the heart and gastrocnemius muscle of the water frog Pelophylax ridibundus. Cryobiology. 2013; 67(2):175-83.
17. Mitelman F, Johansson B, Mertens F. The impact of translo¬cations and gene fusionson cancer causation. Nat Rev Cancer. 2007; 7(4): 233-245.
18. Georgescu A, Stoicea M, Comănescu M, et al. Prognostic and predictive significance of the bcl-2/IgH trans¬location in malignant follicular lymphomas. Rom J Morphol Embryol. 2010; 51(4): 687-91.
19. van Oers MH, Tönnissen E, Van Glabbeke M, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010; 28(13): 2246-52.
20. Kornacker M, Kornacker B, Schmitt C, et al. Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma. Ann Hematol. 2009; 88(1): 43-50.
21. Arcaini L, Colombo N, Bernasconi P, et al. Role of the molecular staging and response in the management of follicular lymphoma patients. Leuk Lymphoma. 2006; 47(6): 1018-1022.
22. George G. Chen (ed), Paul B. S. Lai (ed). Apoptosis in Carcinogenesis and Chemotherapy. 2009th Edition. Netherlands. Springer. 2009.
Files
IssueVol 19 No 3 (2025) QRcode
SectionOriginal Article(s)
Keywords
BCL-2; Immunocytochemistry; B-CL; B-lymphoma
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Abass A-E, Babiker I, Mohmmed A, Hamza R, Albashir S, Osman O, Abbas S, Idris A. Immunocytochemical Detection of BCL-2 Protein in Chronic B-Cell Lymphoproliferative Disorders. Int J Hematol Oncol Stem Cell Res. 2025;19(3):210-214.